Alexandria Real Estate Equities, Inc

Análisis de la acción Alexandria Real Estate Equities, Inc (ARE)

$41.620

-0.708 (-1.70%)Al cierre

Loading chart…
Máximo
42.725
Apertura
42.590
Precio medio ponderado por volumen
41.79
Volumen
2.20M
Capitalización
20.35B
Mínimo
41.020
Importe
91.94M
EV/EBITDA, TTM
11.40

Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.

www.are.com

Análisis de IA of Alexandria Real Estate Equities, Inc (ARE)

Vender

Alexandria Real Estate Equities Inc is not a good buy right now due to significant financial instability and negative market sentiment. The current price is $45.51, with an RSI of 23.288 indicating the stock is oversold. Additionally, the stock has experienced a 38.39% decline over the past year, contrasting sharply with the S&P 500's 17.2% gain, suggesting a lack of investor confidence. The main risk is the company's high debt-to-equity ratio of 66.85%, which raises concerns about its financial health and ability to recover.

Recomendaciones de analistas (12)

+36.59% de potencial alcista
Comprar
7 Comprar
5 Mantener
0 Vender
Actual: 41.62
Mínimo
41.00
Promedio
56.85
Máximo
67.00

BMO Capital

2026-10-12

Precio objetivo

$41

Market Perform

JPMorgan

2026-09-24

Precio objetivo

$56

Infraponderar

Evercore ISI

2026-09-21

Precio objetivo

$59

Superar al mercado

Baird

2026-08-24

Precio objetivo

$52

Neutral

BofA

2026-08-24

Precio objetivo

$55

Neutral

Métricas de valoración

El PER previsto actual de Alexandria Real Estate Equities, Inc (ARE) es 16.69, frente a su media de 5 años de 47.14.

PER previsto

Valor razonable
Media 5A P/E
47.14
P/E actual
16.69
Sobrevalorada
82.83
Infravalorada
11.45

EV/EBITDA previsto

Infravalorado
Media 5A EV/EBITDA
20.36
EV/EBITDA actual
11.40
Sobrevalorada
28.36
Infravalorada
12.35

Precio/ventas previsto

Infravalorado
Media 5A P/S
6.72
P/S actual
2.83
Sobrevalorada
9.57
Infravalorada
3.88

Escenarios de precio de Alphio AI para ARE

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%ARE

$70.33

Precio del escenario

B

Base

Base · 50%ARE

$69.46

Precio del escenario

B

Bajista

Bajista · 25%ARE

$59.44

Precio del escenario

Ballenas con ARE en cartera

S

Stichting Pensioenfonds ABP

+ Con en carteraARE

+2.20%

Rentabilidad a 3 meses

C

Clal Financial Management Ltd

+ Con en carteraARE

-2.97%

Rentabilidad a 3 meses

Q

Quinn Opportunity Partners LLC

+ Con en carteraARE

-6.09%

Rentabilidad a 3 meses

C

CenterSquare Investment Management LLC

+ Con en carteraARE

-8.94%

Rentabilidad a 3 meses

Preguntas frecuentes sobre ARE, respondidas por Alphio AI

Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry. It operates in the Real Estate sector (REAL ESTATE INVESTMENT TRUSTS industry).

Alexandria Real Estate Equities Inc is not a good buy right now due to significant financial instability and negative market sentiment. The current price is $45.51, with an RSI of 23.288 indicating the stock is oversold. Additionally, the stock has experienced a 38.39% decline over the past year, contrasting sharply with the S&P 500's 17.2% gain, suggesting a lack of investor confidence. The main risk is the company's high debt-to-equity ratio of 66.85%, which raises concerns about its financial health and ability to recover.

12 analysts cover ARE: 7 rate it Buy, 5 Hold and 0 Sell. The average price target is 56.85.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar